On August 2, 2024, at the Dabaco Vietnam Group (code: DBC), the representative of the Animal Health Department – Mr. Nguyen Van Long, Director, announced and granted the Good Manufacturing Practice (GMP-WHO) certificate to Dacovet Pharmaceutical and Animal Health Company under Dabaco.
This event marks a significant turning point for Dabaco and testifies to their determination, bold thinking, and professional and reputable leadership. For Dabaco, entering the vaccine production field is a perfect fit for their closed-loop production model. The GMP-WHO certification of the factory also assures farmers of the quality of the Group’s vaccines.
The Dacovet vaccine factory began construction in August 2022, with a total investment of approximately VND 300 billion and a capacity of 200 million doses/year. From the outset, the Group focused its resources on constructing the factory with a synchronized and modern system of equipment and technology, as well as quality control laboratories, including state-of-the-art equipment imported from developed countries such as Germany and Italy. These ensure technical expertise, sterility, safety, and efficacy.
In addition, the Group collaborates with leading professors and scientists, both domestic and foreign, and prominent vaccine businesses. They also prepare a high-quality workforce to participate in researching and producing the ASF2 porcine epidemic diarrhea vaccine. With serious and well-planned investments and in-depth international cooperation, Dabaco is fully confident in producing African swine fever vaccines that meet domestic demand and aim for export.
The leadership of the Animal Health Department and the GMP Inspection Team highly appreciated Dabaco’s large-scale, well-planned, and modern investment in the vaccine factory. They expressed their belief that Dabaco would make significant contributions to the field of pharmaceuticals and animal health in Vietnam, which is challenging yet full of potential.
Throughout the research, testing, and completion of vaccine circulation procedures and GMP-WHO certification, Dabaco received close guidance from Deputy Minister of Agriculture and Rural Development Phung Duc Tien, as well as agencies under the Ministry, especially the Animal Health Department and its subordinate agencies.
Given the current reality, African swine fever still occurs in many localities in the country and the region and worldwide. Meanwhile, no country has announced the successful commercial production of a vaccine. Dabaco’s success will have a significant impact on protecting the Group’s pig herd and the domestic pig industry and is expected to create opportunities for exporting ASF vaccines made in Vietnam globally.
Currently, Dabaco is expediting the final steps to complete the synchronization procedures for the factory and testing before commercializing the product to the market as soon as possible.